Compare
Viatris Inc vs Zoetis Inc. vs Organon & Co. vs Abbott Laboratories
| Latest fiscal year | Viatris Inc VTRS | Zoetis Inc. ZTS | Organon & Co. OGN | Abbott Laboratories ABT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $14.30B | $9.47B | $6.22B | $44.33B |
| Revenue growth (YoY) | -3.0% | +2.3% | -2.9% | +5.7% |
| Gross margin | 35.1% | 71.8% (computed) | 53.3% | 56.4% (computed) |
| Operating margin | -18.6% | n/a | n/a | 18.2% |
| Net margin | -24.6% | 28.2% | 3.0% | 14.7% |
| Net income | -$3.51B | $2.67B | $187.00M | $6.52B |
| EPS (Diluted) | -$3.00 | $6.02 | $0.72 | $3.72 |
| Operating cash flow | $2.32B | $2.90B | $700.00M | $9.57B |
| Free cash flow | $1.94B | $2.28B | $538.00M | $7.39B |
| Cash & equivalents | $1.32B | n/a | $574.00M | $8.52B |
| Total assets | $37.19B | $15.47B | $12.87B | $86.71B |
| Total liabilities | $22.48B | $12.14B | $12.12B | n/a |
| Shareholders' equity | $14.71B | $3.33B | $752.00M | $52.13B |
| Return on year-end equity | -23.9% | 80.2% | 24.9% | 12.5% |
| Shares outstanding | n/a | 424.93M | 260.32M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Viatris Inc | Zoetis Inc. | Organon & Co. | Abbott Laboratories |
|---|---|---|---|---|
| Latest | $14.30B Ended 2025-12-31 | $9.47B Ended 2025-12-31 | $6.22B Ended 2025-12-31 | $44.33B Ended 2025-12-31 |
| 1 year earlier | $14.74B Ended 2024-12-31 | $9.26B Ended 2024-12-31 | $6.40B Ended 2024-12-31 | $41.95B Ended 2024-12-31 |
| 2 years earlier | $15.43B Ended 2023-12-31 | $8.54B Ended 2023-12-31 | $6.26B Ended 2023-12-31 | $40.11B Ended 2023-12-31 |
| 3 years earlier | $16.26B Ended 2022-12-31 | $8.08B Ended 2022-12-31 | $6.17B Ended 2022-12-31 | $43.65B Ended 2022-12-31 |
| 4 years earlier | $17.89B Ended 2021-12-31 | $7.78B Ended 2021-12-31 | $6.30B Ended 2021-12-31 | $43.08B Ended 2021-12-31 |